MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: paclitaxel

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

European Journal of Surgical Oncology 2017 Janury 29 [Epub ahead of print] [Link] Sugarbaker PH, Chang D Abstract PURPOSE: Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases […]

Comments Off on Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.

Biomedicine & Pharmacotherapy 2017 January [Epub ahead of print] [Link] Petrella F, Coccè V, Masia C, Milani M, Salè E, Alessandri G, Parati 4, Sisto F, Pentimalli F, Brini AT, Pessina A, Spaggiari L Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare fatal asbestos-related malignancy originating in the mesothelial cells of the pleura. A […]

Comments Off on Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.

Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma

Biomaterials 2016 June 22 [Epub ahead of print] [Link] Liu R, Colby AH, Gilmore D, Schulz M, Zeng J, Padera RF, Shirihai O, Grinstaff MW, Colson YL Abstract The treatment outcomes for malignant peritoneal mesothelioma are poor and associated with high co-morbidities due to suboptimal drug delivery. Thus, there is an unmet need for new […]

Comments Off on Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma

Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors

Investigational New Drugs. 2008 Oct 28. [Epub ahead of print] [Link] Hanauske AR, Dumez H, Piccart M, Yilmaz E, Graefe T, Gil T, Simms L, Musib L, Awada A. St. Georg Hospital, Ahrensburger Weg 129b, 22359, Hamburg, Germany, hanauskeax@lilly.com. Abstract The objectives of this phase I study were to determine the maximum tolerated dose (MTD), […]

Comments Off on Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Therapeutics and Clinical Risk Management. 2008 Jun;4(3):579-85. [Link] Felip E, Rosell R. Vall d’Hebron University Hospital Barcelona, Spain. Abstract NSCLC accounts for 80% of all cases of lung cancer, which is the leading cause of cancer mortality. The majority of NSCLC patients present with advanced, unresectable disease, which remains incurable. In advanced disease, chemotherapy with […]

Comments Off on Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance

International Journal of Cancer. 2008 Jun 4. [Epub ahead of print] [Link] Barone-Adesi F, Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. Unit of Cancer Epidemiology, CeRMS and Center for Oncologic Prevention Piemonte, University of Turin, Turin, Italy. Abstract Models based on the multistage theory of carcinogenesis predict that the rate […]

Comments Off on Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance

Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599

Clinical Lung Cancer. 2008 Mar;9(2):102-5. [Link] Somer RA, Sherman E, Langer CJ. Department of Medical Oncology, Cooper Medical Center, Cherry Hill, NJ, USA. Abstract Background: In a previous randomized phase II trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients naive to chemotherapy with advanced non-small-cell lung cancer (NSCLC), median survival ranged from […]

Comments Off on Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599

Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel

European Journal of Gynaecological Oncology. 2007;28(4):322-3. [Link] Takeuchi K, Fujimoto M, Tsujino T, Takeda Y, Yoshida S. Department of Obstetrics and Gynecology, Hyogo Prefectural Tsukaguchi Hospital, Amagasaki, Japan. Abstract Background: The results of treatment of malignant peritoneal mesothelioma are quite unsatisfactory, especially in the later stages of the disease, regardless of the treatment modality employed. […]

Comments Off on Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel